ClinicalTrials.gg
Status unknownNCT05799716Updated Apr 5, 2023

Treating Donors With Intravenous Immunoglobulin to Reduce Donor-Derived Infections

A Phase 4 interventional study of IVIG in Viremia, Bacteremia and Acute Rejection of Renal Transplant, sponsored by Shanghai Changzheng Hospital. Status unknown. Open to participants aged 6 Years to 65 Years. Per ClinicalTrials.gov, last updated 2023-04-05.

Sponsored by Shanghai Changzheng Hospital · Phase 4, Interventional, and Prevention

The sponsor has not verified this record recently (last verified Mar 2023), so the status shown — last known as Not yet recruiting — may be out of date.
Phase
Phase 4
Study type
Interventional
Enrollment
40
Allocation
Randomized
Ages
6 Years to 65 Years
Sex
All
01

Study summary

The goal of this clinical trial is to learn about the benefit of IVIG in donor-derived infections and the potential immunomodulatory effect on transplanted organs. The main questions it aims to answer are:

  1. How effective IVIG is in preventing donor-derived infections
  2. Does IVIG has potential immunomodulatory effect on transplanted organs
Read the detailed description

Donor-derived infections are defined as any infection present in the donor that is transmitted to one or more recipient. Donor-derived infections can be categorized into two groups: "expected" and "unexpected" infections. Expected transmissions occur when the donor is known to have an infection, as demonstrated by positive serology or nucleic acid test (NAT) result for cytomegalovirus (CMV), Epstein-Barr virus (EBV) or hepatitis B and C, or positive cultures in the donor at the time of donation. Unexpected transmissions may occur despite current screening strategies and are not expected in the donor at the time of organ placement.

Intravenous immunoglobulins (IVIG) are produced by pooling together of serum immunoglobulins from multiple donors, and are known to have powerful immunomodulatory and anti-inflammatory functions in vitro and in vivo. The goal of this study is to figure out the benefit of IVIG in donor-derived infections and the potential immunomodulatory effect on transplanted organs.

02

Conditions studied

  • Viremia
  • Bacteremia
  • Acute Rejection of Renal Transplant

Browse trials for

Keywords

  • IVIG Infection
03

In context

Viremia

57 studies on the registry are indexed under Viremia; 12 are open to participants now.

This study's planned enrollment of 40 is below the median of 87 across 45 interventional studies indexed under Viremia.

Browse Viremia studies →

Lead sponsor

Shanghai Changzheng Hospital is the lead sponsor of 128 studies on the registry; 60 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
6 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Any person approved as a transplant donor with recipient who has never undergone a previous transplantation
  • Transplant donor must be 6 years old or older
  • They must have provided signed
  • The donors must be willing to contribute samples of blood

Exclusion criteria

Exclusion Criteria:

  • Any potential transplant donor who is receiving or have received anti-herpes medication in the past week
  • Any potential transplant donor to a recipient who has received a previous solid organ transplant
  • Any potential transplant donor who is due to medical disease and/or immunosuppressive or immunomodulating medications
  • Any potential transplant donor who is on
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 4
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Outcomes assessor)
Enrollment
40 participants (estimated)

Study arms

  • Experimental
    IVIG

    Drug: IVIG

  • No intervention
    Sham

Interventions

06

What researchers measure

Primary outcomes

  1. Next-Generation Sequencing (NGS) Results of Bacteremia or Viremia in Transplant Recipient

    NGS is a technology for determining the sequence of DNA or RNA to study genetic variation associated with diseases like bacteremia and viremia.

    Time frame: 14 days

  2. Incidence of Bacteremia or Viremia in Transplant Recipient

    Time frame: 14 days

Secondary outcomes

  1. Incidence of Acute Rejection in Transplant Recipient

    Time frame: 1 month

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Apr 2023; primary completion for Apr 2024, 12 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 13, 2023
First posted
Apr 5, 2023
StartEst.
Apr 1, 2023
Primary completionEst.
Apr 1, 2024
CompletionEst.
Sep 1, 2024
Last update
Apr 5, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 5, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05799716
Responsible party
Sponsor
First posted
Apr 5, 2023
Start date
Apr 1, 2023 (estimated)
Primary completion
Apr 1, 2024 (estimated)
Completion
Sep 1, 2024 (estimated)
Last update
Apr 5, 2023

Study contacts

Jinghui Yang
Contact
yjh@smmu.edu.cn
021-81885756

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Mar 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Immunoglobulins, Intravenous

Start the discussion